Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Novartis Invests $10 Million in Anti-Cancer Company Ayala Pharmaceuticals
#Investment
Dec 23, 2018
en.globes.co.il
Ayala signs licensing deal with Novartis for blood cancer drug
#Investment #Partners
Oct 17, 2018
en.globes.co.il
Novartis to invest in $60m Gamida Cell Nasdaq IPO
#Public Trading #Investment
Feb 15, 2015
www.globes.co.il
Novartis seeks new Israeli technologies
#Investment #Partners
Dec 15, 2009
www.haaretz.com
Optonol: Reaping $180m from a device the size of a grain of rice
#Acquisition
About
Novartis AG focuses its business on three divisions: pharmaceuticals, eye care (Alcon), and generics (Sandoz). These three divisions are supported by the research organization, the Novartis Institutes for BioMedical Research, and a centralized services group, Novartis Business Services, to facilitate collaboration across the divisions and drive efficiency and productivity gains.
In Israel, in addition to the marketing department, Novartis has a division engaged in medical research and development of new drugs and a wide range of clinical research activities. In 2009, Alcon, a subsidiary of Novartis, acquired Optonol, a company that develops devices for ophthalmologic applications and glaucoma surgery. Since its acquisition, Optonol operates as a subsidiary of the company.
Novartis also operates in Israel a Cyber Security research center. Novartis is also present in Israel, through its innovation center BIOME.